# Nuclide record rayzebio (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/rayzebio/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "rayzebio" ;
  schema:name "RayzeBio (BMS)"@en ;
  schema:description "RayzeBio is the actinium-225 radiopharma company that BMS bought for $4.1B; its RYZ101 is in phase 3."@en ;
  schema:url <https://nuclide.cc/companies/rayzebio/>, <https://www.rayzebio.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.rayzebio.com> ;
  schema:addressCountry "US" ;
  nuclide:related <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:drugs <https://nuclide.cc/drugs/ryz101/> ;
  nuclide:trials <https://nuclide.cc/trials/nct06590857/>, <https://nuclide.cc/trials/nct06726161/> .